


# Identification and characterisation of host-pathogen protein-protein interactions in the blood stages of malaria



**Abigail Perrin**

Wellcome Trust Sanger Institute

University of Cambridge - Emmanuel College

This dissertation is submitted for the degree of

*Doctor of Philosophy*

December

2014



For Julia, Nick and Tim



## **Declaration**

I hereby declare that the contents of this thesis are original and have not been submitted in whole or in part for consideration for any other degree or qualification in this, or any other, University. This thesis is the result of my own work and includes nothing which is the outcome of work done in collaboration, except where specifically indicated in the text. This thesis does not exceed the word limit set by the Faculty of Biology.

Abigail Perrin  
2014



## Acknowledgements

First and foremost I would like to thank my supervisor, Dr Gavin Wright, for his direction, advice and support at every stage of this work. I'd also like to thank Dr Julian Rayner for his guidance. I've been very privileged to work in such a supportive team and thank the members of the Cell Surface Signalling Laboratory, past and present. In particular, I'd like to mention Josefin for all her help getting to grips with SPR and Cecile, Zenon and Madushi who have so readily shared their reagents and technical insights. From other groups at the Sanger Institute, I'd like to thank Will Cheng and Bee Ling Ng for their flow cytometry training and advice, and Lu Yu for running my mass spectrometry samples. I'm also grateful to Harriet McKinney and Steve Garner for all their help with platelet-staining experiments.

The support and friendship of some very special people has made these four years pass so quickly. I'm so lucky to have shared this time with the excellent scientists of the Sanger Institute, the community of graduate students across the University, the incredible teams and coaches of Emmanuel BC, and some wonderful housemates. To mention just a few important people by name: Daniela, Helen, Rob, John, Eva, Kim, Cat, Max, Tom, Lizzy, Olivia, Emily, Mary, Ruth - you've been amazing!

This work was generously supported by both the Medical Research Council and Wellcome Trust.







## Abstract

Malaria is a widespread and serious disease which affects billions of people. Protein-protein interactions occurring between host and *Plasmodium* parasites are critical to the pathogenesis of malaria and thus represent prime targets for greatly-needed novel therapeutics. Identifying these host-pathogen interactions is challenging, but recent advances in our understanding of parasite biology and in high-throughput biomolecular interaction detection methods have paved the way to a number of successes.

In this work I produced a library of recombinant *Plasmodium falciparum* proteins to screen for interactions with human receptors in a number of high-throughput assays. Using an established ELISA-based protein-protein interaction detection method, I identified an interaction between *P. falciparum* merozoite protein 7 (PfMSP7) and human P-selectin (SELP). I used surface plasmon resonance and flow cytometry approaches to validate this interaction and, by screening more widely across the MSP7 protein family, identified that SELP-binding is a conserved property of multiple MSP7s in at least three *Plasmodium* species. The evolutionary conservation indicates that SELP-MSP7 interactions might have an important function in malaria. Isolating the interacting regions of SELP and PfMSP7 to the secreted, flexible N-terminus of PfMSP7 and the known ligand-binding domains of SELP led to a hypothesis that PfMSP7 could prevent the leukocyte recruitment and activation properties of SELP. I used PfMSP7 to block the interactions between SELP and leukocyte ligands *in vitro*, providing support to this hypothesis. Further evidence will be required to determine whether *Plasmodium* MSP7 proteins and their interactions with SELP mediate an immunomodulatory mechanism in malaria, and whether the MSP7 proteins represent useful therapeutic targets.

I also developed a biochemical co-purification assay aiming to detect additional interactions between recombinant *P. falciparum* merozoite extracellular proteins and those present in human serum. This assay was successful in detecting previously-identified interactions but did not identify novel binding partners for 56 *P. falciparum* ligands. By expanding the screen or by decreasing its stringency this method could facilitate the identification of further receptors for *Plasmodium* ligands which could in turn, like the interaction between SELP and MSP7s, aid our understanding of how host and pathogen interact to cause disease.



# Contents

<b>Contents</b>	<b>i</b>
<b>List of Figures</b>	<b>vii</b>
<b>List of Tables</b>	<b>xi</b>
<b>1 General introduction</b>	<b>13</b>
1.1 An introduction to malaria . . . . .	13
1.1.1 Malaria as a major global health problem . . . . .	13
1.1.2 <i>Plasmodium</i> parasites cause malaria . . . . .	14
1.1.3 <i>Plasmodium</i> merozoites invade red blood cells . . . . .	16
1.1.3.1 Merozoite structure . . . . .	16
1.1.3.2 RBC invasion and parasitism . . . . .	17
1.1.4 Malaria can have life-threatening sequelae . . . . .	18
1.1.5 Natural immunity to malaria provides incomplete protection from <i>Plas-</i> <i>modium</i> infections . . . . .	19
1.1.5.1 Innate and adaptive immune responses . . . . .	19
1.1.5.2 Genetic resistance to malaria . . . . .	21
1.1.6 Blood-stage <i>P. falciparum</i> parasites are highly adept at immune-evasion	22
1.1.7 Current anti-malarial measures . . . . .	23
1.1.7.1 Chemotherapeutic agents . . . . .	23
1.1.7.2 Environmental management . . . . .	24
1.1.8 Threats to the elimination of malaria . . . . .	24
1.1.8.1 Antimalarial drug resistance . . . . .	24
1.1.8.2 Insecticide-resistant mosquitoes . . . . .	25
1.1.8.3 Challenges of vaccine development . . . . .	25
1.1.9 Research resources . . . . .	27

---

1.2	Protein-protein interactions in malaria . . . . .	28
1.2.1	Parasites interact directly with their human host . . . . .	28
1.2.1.1	RBC invasion . . . . .	29
1.2.1.2	pRBC/host interactions . . . . .	29
1.2.1.3	Sporozoite/host interactions . . . . .	30
1.2.1.4	Identification of novel interactions can provide important insights into parasite biology . . . . .	30
1.2.2	Interaction discovery . . . . .	31
1.2.2.1	Studies on candidate proteins . . . . .	31
1.2.2.2	Screening approaches . . . . .	32
1.2.2.3	<i>In vitro</i> validation and kinetic analysis of interactions . . . . .	33
1.2.3	Identifying new interactions: Approaches in the Wright Lab . . . . .	34
1.2.3.1	A mammalian expression system for <i>Plasmodium</i> proteins . . . . .	34
1.2.3.2	AVEXIS . . . . .	34
1.3	Scope of this thesis . . . . .	36
<b>2</b>	<b>Materials and Methods</b> . . . . .	<b>39</b>
2.1	Protein production . . . . .	39
2.1.1	Plasmid preparation . . . . .	39
2.1.1.1	PCR . . . . .	41
2.1.1.2	Restriction-ligation cloning . . . . .	41
2.1.2	Protein expression using HEK293 cells . . . . .	42
2.1.2.1	Cell culture . . . . .	42
2.1.2.2	Transfection . . . . .	42
2.1.2.3	Collection . . . . .	43
2.2	Protein purification and quantification . . . . .	43
2.2.1	Immobilised metal ion affinity chromatography . . . . .	43
2.2.2	Size-exclusion chromatography . . . . .	43
2.2.3	Determination of protein concentration . . . . .	44
2.2.4	SDS-PAGE . . . . .	44
2.2.5	Western blotting . . . . .	44
2.2.6	Polyclonal antibody production and purification . . . . .	45
2.3	AVEXIS . . . . .	45
2.3.1	Standardisation . . . . .	45
2.3.1.1	ELISA . . . . .	46

---

2.3.1.2	Nitrocefin hydrolysis assay . . . . .	47
2.3.1.3	Data presentation . . . . .	48
2.4	SELP-ligand interaction blocking . . . . .	48
2.4.1	sLe <sup>X</sup> -SELP interaction blocking . . . . .	48
2.4.2	THP1 binding assay . . . . .	49
2.5	Surface plasmon resonance . . . . .	49
2.6	Flow cytometry . . . . .	50
2.6.1	Labelling RBC surface proteins . . . . .	50
2.6.2	Detecting protein-protein interactions on the surface of HEK cells . . . . .	50
2.6.3	Platelet staining . . . . .	51
2.7	Biochemical co-purifications . . . . .	51
2.7.1	Mass spectrometry . . . . .	52
<b>3</b>	<b>Identification and validation of an interaction between SELP and PfMSP7</b>	<b>59</b>
3.1	Introduction . . . . .	59
3.1.1	Rationale for screening . . . . .	59
3.1.2	Selection of proteins for screening . . . . .	60
3.1.3	A brief introduction to SELP and PfMSP7 . . . . .	62
3.2	Results . . . . .	62
3.2.1	PfMSP7 and SELP interacted in an AVEKIS screen . . . . .	62
3.2.2	The recombinant SELP and PfMSP7 proteins were biologically active	64
3.2.3	The SELP/PfMSP7 interaction could be blocked by an anti-SELP mAB	67
3.2.4	PfMSP7 bound to recombinant SELP at the cell surface . . . . .	67
3.2.5	Recombinant PfMSP7 formed metastable oligometric complexes in solution . . . . .	71
3.2.5.1	The flexible N-terminus of PfMSP7 was responsible for self-oligomerisation . . . . .	73
3.2.5.2	'Intrinsic disorder' in PfMSP7 . . . . .	73
3.2.6	PfMSP7 binding to SELP was observed using SPR . . . . .	74
3.3	Discussion . . . . .	78
3.3.1	Multiple biochemical assays indicate that PfMSP7 and SELP interact, but oligomerisation of PfMSP7 may be required . . . . .	78
3.3.2	Recombinant SELP is prone to non-specific interactions, but multiple lines of evidence support the validity of its interaction with PfMSP7 . . . . .	79

<b>4 Biochemical characterisation of the interactions between SELP and <i>Plasmodium</i> MSP7s</b>	<b>83</b>
4.1 Introduction . . . . .	83
4.1.1 The <i>Plasmodium</i> MSP7 family . . . . .	83
4.1.1.1 MSP7s in a genomic context . . . . .	83
4.1.1.2 MSP7 protein expression . . . . .	85
4.1.1.3 PfMSP7 and PbMSP7 are associated with RBC invasion, but may perform additional functions . . . . .	86
4.1.1.4 The <i>P. falciparum</i> MSRPs have no known function . . . . .	87
4.1.2 The human selectins . . . . .	88
4.1.2.1 The selectin proteins . . . . .	88
4.1.2.2 SELP-ligand interactions are important in inflammation and blood coagulation . . . . .	89
4.1.2.3 SELP is known to contribute to malarial pathology . . . . .	90
4.2 Results . . . . .	90
4.2.1 Characterisation of PfMSP7 binding to selectins . . . . .	90
4.2.1.1 The C-type lectin and EGF-like domains of SELP were re- quired to bind PfMSP7 . . . . .	90
4.2.1.2 PfMSP7 bound to SELP and interacted weakly with SELL . . . . .	92
4.2.1.3 Naturally-occurring SNPs within SELP's binding domain did not affect binding to PfMSP7 without compromising protein function . . . . .	92
4.2.2 Characterisation of SELP binding to <i>Plasmodium</i> MSP7-proteins . . . . .	96
4.2.2.1 The N-terminus of PfMSP7 bound to SELP . . . . .	96
4.2.2.2 SELP-binding was a characteristic of multiple members of the <i>P. falciparum</i> MSP7 family . . . . .	96
4.2.2.3 The MSP7-SELP interaction was conserved across <i>Plas-</i> <i>modium</i> species . . . . .	99
4.2.3 Investigating the influence of PfMSP7 on known binding interactions of SELP . . . . .	99
4.2.3.1 PfMSP7 blocked the interaction between sLe <sup>X</sup> and SELP . . . . .	99
4.2.3.2 PfMSP7 could block cellular adhesion to SELP . . . . .	100
4.3 Discussion . . . . .	102
4.3.1 Further evidence that the PfMSP7-SELP interaction is biologically relevant . . . . .	102

---

4.3.2	The SELP-PfMSP7 interaction is unlikely to be involved in RBC invasion . . . . .	103
4.3.3	SELP-binding may have anti-inflammatory function . . . . .	104
4.3.4	Interactions between SELP and MSP7s could modulate a range of other cellular processes, including cytoadhesion. . . . .	107
<b>5</b>	<b>Development of a biochemical co-purification assay to detect interactions between <i>Plasmodium</i> merozoite proteins and human serum proteins</b>	<b>109</b>
5.1	Introduction . . . . .	109
5.1.1	<i>Plasmodium</i> merozoites are exposed to human serum . . . . .	109
5.1.2	A modified biochemical co-purification assay to discover novel merozoite-serum interactions . . . . .	112
5.2	Assay development . . . . .	112
5.2.1	Requirements of a sensitive assay . . . . .	112
5.2.2	Ensuring specific capture of biotinylated merozoite proteins . . . . .	114
5.2.3	Optimising elution efficiency . . . . .	116
5.2.4	Optimising washing steps . . . . .	117
5.2.5	Theoretical assessment of assay sensitivity . . . . .	120
5.3	Results . . . . .	123
5.3.1	The optimised assay reproducibly detected the interaction between PfMSP3.4 and IgM . . . . .	123
5.3.2	The PfMSP3.4 bait could be used to co-purify IgM with a very high sensitivity . . . . .	127
5.3.3	The biochemical co-purification assay was capable of detecting a low affinity interaction . . . . .	127
5.3.4	Serum interaction screens using purified merozoite baits . . . . .	129
5.3.5	High-throughput screening of the merozoite protein library . . . . .	131
5.4	Discussion . . . . .	139
5.4.1	Strengths of the assay . . . . .	139
5.4.2	Potential improvements to the assay . . . . .	139
<b>6</b>	<b>General discussion</b>	<b>143</b>
6.1	Summary of results . . . . .	143
6.2	Implications of SELP/MSP7 interactions . . . . .	144
6.2.1	A possible mechanism underlying MSP7-knockout phenotypes . . . . .	144
6.2.2	Implications for vaccine development . . . . .	145

---

6.3	Summary of potential future experiments . . . . .	146
6.3.1	Biochemical details of SELP/MSP7-family protein-protein interactions	146
6.3.2	Determination of the function of the SELP/MSP7 interaction . . . . .	147
6.3.3	Expansion and improvement of screening for interactions occurring between <i>Plasmodium</i> proteins and human receptors . . . . .	149
6.4	Concluding remarks . . . . .	152
<b>A</b>	<b>Glossary</b>	<b>153</b>
A.1	Abbreviations Used in this work . . . . .	153
A.2	Protein names . . . . .	155
A.3	Weblinks . . . . .	156
	<b>References</b>	<b>157</b>



# List of Figures

1.1	Parasite life cycle in the human host . . . . .	15
1.2	Merozoite structure and RBC invasion ligands . . . . .	16
1.3	Acquisition of immunity to malaria . . . . .	20
1.4	AVEXIS as a highly sensitive interaction screening method . . . . .	35
2.1	Construction of plasmids for protein expression . . . . .	40
2.2	Standardisation of bait proteins by ELISA . . . . .	46
2.3	Standardisation of prey protein by measuring nitrocefin hydrolysis . . . . .	47
2.4	HEK293F cell-surface binding assay . . . . .	53
3.1	PfMSP7 is proteolytically processed . . . . .	63
3.2	SELP bait interacted with PfMSP7 prey . . . . .	65
3.3	Recombinant, soluble SELP and PfMSP7 preparations were biochemically active . . . . .	66
3.4	An anti-SELP mAB blocked the SELP/PfMSP7 interaction . . . . .	68
3.5	Development of flow cytometry-based assay to measure protein binding to HEK cells . . . . .	69
3.6	PfMSP7 pentamers bound specifically to SELP at the cell surface . . . . .	70
3.7	PfMSP7 formed oligomers <i>in vitro</i> . . . . .	72
3.8	PfMSP7-N showed similar oligomerisation behaviour to full-length PfMSP7 . . . . .	75
3.9	PfMSP7 bound specifically to SELP in SPR experiments . . . . .	76
3.10	Purified SELP bound to SPR chips . . . . .	77
3.11	Purified SELP bait interacted promiscuously in another AVEXIS screen . . . . .	79
3.12	Platelet staining assays were optimised but unsuccessful due to antibody binding to the platelet surface . . . . .	81
4.1	<i>MSP7</i> gene organisation and nomenclature in different <i>Plasmodium</i> species . . . . .	84
4.2	The CTL and EGF domains of SELP were essential for PfMSP7 binding . . . . .	91

---

4.3	Limited evidence for SELP and SELE binding to PfMSP7 . . . . .	93
4.4	Functional SELP variants retained binding to PfMSP7 . . . . .	95
4.5	The N-terminus of PfMSP7 bound to SELP . . . . .	97
4.6	SELP-binding is conserved in multiple <i>Plasmodium</i> MSP7s . . . . .	98
4.7	PfMSP7 could block the SELP/sLe <sup>X</sup> interaction . . . . .	100
4.8	PfMSP7 could block the specific adhesion of THP1 cells to SELP . . . . .	101
4.9	Selectins were not detectable on the RBC surface . . . . .	104
4.10	PfMSP7 was not detected in schizont lysate . . . . .	105
4.11	Hypothesised anti-inflammatory activity of PfMSP7 . . . . .	106
5.1	Protein composition of human serum . . . . .	111
5.2	A biochemical co-purification assay for the discovery of merozoite-serum protein interactions . . . . .	113
5.3	Biotinylated merozoite proteins were specifically captured on paramagnetic beads . . . . .	115
5.4	Identification of appropriate elution buffers . . . . .	116
5.5	Theoretical assessment of wash-step dependency of interaction detection . . . . .	118
5.6	Experimental optimisation of washing steps using negative and positive control bait proteins . . . . .	119
5.7	Theoretical determination of the range of detectable interactions . . . . .	122
5.8	Identification of IgM from PfMSP3.4 biochemical co-purification experiments . . . . .	124
5.9	PfMSP3.4 was used to detect IgM with high sensitivity . . . . .	126
5.10	PfRH5-coated beads could be used to co-purify BSG . . . . .	128
5.11	An initial serum protein interaction screen identified no novel interactions . . . . .	130
5.12	PfMSP3-family serum biochemical co-purification screen revealed no novel interactions . . . . .	132
5.13	PfMSP7-family serum biochemical co-purification screen revealed no novel interactions . . . . .	133
5.14	Recombinant protein from HEK cell culture supernatant could saturate beads . . . . .	135
5.15	A pilot high-throughput screen identified candidate <i>P. falciparum</i> proteins for further investigation . . . . .	136
5.16	Additional high-throughput interaction screens . . . . .	137
5.17	Follow-up screening did not validate potential hits from high-throughput screening . . . . .	138

---

6.1	Predicted disorder is common to all <i>P. falciparum</i> MSP7-family proteins, but lower in PfMSRP2 . . . . .	148
6.2	BSI as a method to discover and measure protein-RBC interactions . . . . .	151



# List of Tables

2.1	PCR primers . . . . .	54
2.2	SELP protein fragment boundaries . . . . .	55
2.3	PfMSP7 protein fragment boundaries . . . . .	55
2.4	Summary of expression plasmids used . . . . .	56
2.5	Summary of expression plasmids used (continued) . . . . .	57
3.1	Platelet bait proteins selected for AVEXIS screening . . . . .	60
3.2	Merozoite prey proteins selected for AVEXIS screening . . . . .	61
5.1	Peptides identified by mass spectrometry from hypothesised IgM heavy chain band from PfMSP3.4 biochemical purification . . . . .	125
5.2	Peptides identified by mass spectrometry from hypothesised IgM heavy chain band from PfMSP3.8 biochemical purification . . . . .	125
5.3	<i>P. falciparum</i> merozoite proteins screened against human serum . . . . .	140
5.4	<i>P. falciparum</i> merozoite proteins screened against human serum (continued) .	141

